United Therapeutics Corp
NASDAQ:UTHR

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
NASDAQ:UTHR
Watchlist
Price: 400.52 USD 5.27% Market Closed
Market Cap: 18.1B USD

Intrinsic Value

The intrinsic value of one UTHR stock under the Base Case scenario is 300.39 USD. Compared to the current market price of 400.52 USD, United Therapeutics Corp is Overvalued by 25%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

UTHR Intrinsic Value
300.39 USD
Overvaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
United Therapeutics Corp

What is Valuation History?
Compare UTHR to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Significant reliance on its pulmonary arterial hypertension (PAH) franchise exposes United Therapeutics to competition from newer therapies and potential generic entrants, which could erode its leading market share and pricing power.

Bull Theses

United Therapeutics has maintained a strong foothold in PAH treatments with established therapies such as Tyvaso, Orenitram, and Remodulin, supported by steady demand and favorable reimbursement, driving stable cash flow.

Show More Less
How do you feel about UTHR?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about United Therapeutics Corp
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
United Therapeutics Corp

Current Assets 3.8B
Cash & Short-Term Investments 3B
Receivables 379.3m
Other Current Assets 398.9m
Non-Current Assets 4.1B
Long-Term Investments 1.9B
PP&E 1.4B
Intangibles 111.5m
Other Non-Current Assets 689.5m
Efficiency

Free Cash Flow Analysis
United Therapeutics Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
United Therapeutics Corp

Revenue
3.1B USD
Cost of Revenue
-339.1m USD
Gross Profit
2.7B USD
Operating Expenses
-1.2B USD
Operating Income
1.5B USD
Other Expenses
-298.8m USD
Net Income
1.2B USD
Fundamental Scores

UTHR Profitability Score
Profitability Due Diligence

United Therapeutics Corp's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROIC
Exceptional Operating Margin
Exceptional ROIC
Strong 3Y Average Operating Margin
70/100
Profitability
Score

United Therapeutics Corp's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

UTHR Solvency Score
Solvency Due Diligence

United Therapeutics Corp's solvency score is 93/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
93/100
Solvency
Score

United Therapeutics Corp's solvency score is 93/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

UTHR Price Targets Summary
United Therapeutics Corp

Wall Street analysts forecast UTHR stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for UTHR is 386.53 USD with a low forecast of 297.95 USD and a high forecast of 535.5 USD.

Lowest
Price Target
297.95 USD
26% Downside
Average
Price Target
386.53 USD
3% Downside
Highest
Price Target
535.5 USD
34% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

United Therapeutics Corp
does not pay dividends
Shareholder Yield

Current shareholder yield for UTHR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

UTHR Insider Trading
Buy and sell transactions by insiders

UTHR News

Other Videos
What is the Intrinsic Value of one UTHR stock?

The intrinsic value of one UTHR stock under the Base Case scenario is 300.39 USD.

Is UTHR stock undervalued or overvalued?

Compared to the current market price of 400.52 USD, United Therapeutics Corp is Overvalued by 25%.

Back to Top